Entera Bio Ltd. (ENTX) Stock Analysis & Investment Frameworks

Entera Bio Ltd. (ENTX) stock analysis on Invetso. Review Entera Bio Ltd.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Entera Bio Ltd. Company Overview

Entera Bio Ltd. Key Financial Metrics

About Entera Bio Ltd.

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

Entera Bio Ltd. Investment Frameworks

Invetso analyzes Entera Bio Ltd. (ENTX) across the following frameworks:

Explore More ENTX Research